Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy

Lancet Oncol. 2004 Jan;5(1):64-5. doi: 10.1016/s1470-2045(03)01327-5.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Male
  • Mycosis Fungoides / complications
  • Mycosis Fungoides / drug therapy*
  • Mycosis Fungoides / pathology
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab